Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

NCT01810042 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG: ranibizumab

Sponsor

Pusan National University Hospital

Collaborators

[object Object]